Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Published:2019-10-21 Issue:12 Volume:71 Page:2100-2111
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Tison Alice¹,Quéré Gilles¹,Misery Laurent¹,Funck‐Brentano Elisa²,Danlos François‐Xavier³,Routier Emilie³,Robert Caroline³,Loriot Yohann³,Lambotte Olivier⁴,Bonniaud Bertille⁵,Scalbert Camille⁶,Maanaoui Sarah⁶,Lesimple Thierry⁷,Martinez Stéphanie⁸,Marcq Marie⁹,Chouaid Christos¹⁰,Dubos Catherine¹¹,Brunet‐Possenti Florence¹²,Stavris Chloé¹³,Chiche Laurent¹³,Beneton Nathalie¹⁴,Mansard Sandrine¹⁵,Guisier Florian¹⁶,Doubre Hélène¹⁷,Skowron François¹⁸,Aubin François¹⁹,Zehou Ouidad²⁰,Roge Christophe²¹,Lambert Mickaël²¹,Pham‐Ledard Anne²²,Beylot‐Barry Marie²²,Veillon Rémi²²,Kramkimel Nora²³,Giacchero Damien²⁴,De Quatrebarbes Julie²⁵,Michel Catherine²⁶,Auliac Jean‐Bernard²⁷,Gonzales Gilles²⁸,Decroisette Chantal²⁵,Le Garff Gwenaelle²⁹,Carpiuc Ioana³⁰,Vallerand Hervé³¹,Nowak Emmanuel¹,Cornec Divi¹,Kostine Marie²²^ORCID,

Affiliation:

1. CHRU Brest Brest France

2. Hôpital Ambroise Paré Boulogne‐BillancourtAP‐HP Boulogne‐Billancourt France

3. Institut Gustave Roussy Villejuif France

4. Hôpital Kremlin‐BicêtreAP‐HP Paris France

5. CHU Dijon Dijon France

6. CHU Lille Lille France

7. Centre Eugène Marquis Rennes France

8. CH Aix‐en‐Provence Aix‐en‐Provence France

9. CHD Vendée La Roche‐sur‐Yon France

10. CHI Créteil Créteil France

11. Centre François Baclesse Caen France

12. CHU Bichat‐Claude BernardAP‐HP Paris France

13. Hôpital Européen Marseille Marseille France

14. CH Le Mans Le Mans France

15. CHU Estaing Clermont‐Ferrand Clermont‐Ferrand France

16. CHU Rouen Rouen France

17. Hôpital Foch Paris France

18. CH Valence Valence France

19. CHU Besançon Besançon France

20. Hôpital Henri MondorAP‐HP Créteil France

21. CH Morlaix Morlaix France

22. CHU Bordeaux Bordeaux France

23. Hôpital CochinAP‐HP Paris France

24. Centre Antoine Lacassagne Nice France

25. CH Annecy Genevois Metz‐Tessy France

26. Groupe Hospitalier de la Région de Mulhouse et Sud Alsace Mulhouse France

27. CH Mantes‐La‐Jolie Mantes‐la‐Jolie France

28. CH Mâcon Mâcon France

29. CH Saint‐Brieuc Saint‐Brieuc France

30. Capio Clinique des Cèdres Cornebarrieu France

31. CHU de Reims Reims France

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41068

Reference52 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases

4. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

5. Cancer immunotherapy comes of age

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Large-scale genome-wide association studies reveal the genetic causal etiology between ankylosing spondylitis and risk of leukemia and lymphocytic malignancies;Frontiers in Oncology;2024-09-10

2. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047);Lung Cancer;2024-08

3. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

4. Pembrolizumab therapy in a patient with NSCLC and bullous pemphigoid: A case report;Oncology Letters;2024-07-31

5. Immune Checkpoint Inhibitor-Induced Psoriasis;Dermatologic Clinics;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3